Drugs / Digoxin
Digoxin
also known as
Lanoxin · digoxine · Digamex · Digaoxin · Digoxin pediatric · Digoxina · Digoxinum · Dynamos · +16 more
Other / unclassified targets HIF1A, PKM via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | LANOXICAPS | — | 1984-09-24 | fda.gov ↗ |
| Approved | US (FDA) | LANOXIN PEDIATRIC | — | 1954-11-16 | fda.gov ↗ |
Trials 203 · started per year
today
US approved 1954
1
1
1
9
1
7
4
7
7
7
7
16
11
8
9
5
9
12
12
10
18
15
19
6
19531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06821594 | Apr → Aug 2025 overdue | benign neoplasm of skin | Jinnah Postgraduate Medical Centre | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT03928210 | Jul 2020 → Dec 2023 | breast cancer | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1157 trials | ||||||
| Phase 1 | NCT07570082 | May → Dec 2026 expected | — | Crinetics Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07550816 | May → Dec 2026 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07565441 | May → Nov 2026 expected | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07567781 | Apr → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07502001 | Apr → Dec 2026 expected | obesity disorder | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07223671 | Dec 2025 → Feb 2026 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT07269756 | Dec 2025 → Mar 2026 | obesity disorder | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07128888 | Nov 2025 → Jul 2026 overdue | obesity disorder | Gan & Lee Pharmaceuticals. | Recruiting | No outcome recorded |
| Phase 1 | NCT07215260 | Nov → Dec 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07118215 | Sep 2025 → Jun 2026 overdue | — | Karuna Therapeutics, Inc. | Recruiting | No outcome recorded |
| Show all 157 trials opens the full record — a long page | ||||||
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07025850 | Aug 2025 → Jan 2027 expected | colorectal carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06613477 | Oct 2024 → Nov 2026 expected | univentricular cardiopathy | Duke University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06030622 | Apr → Dec 2024 | malignant pancreatic neoplasm | State University of New York - Downstate Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT04044001 | Nov 2019 → Mar 2022 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 1/2 | NCT03113071 | Jun 2017 → Jan 2019 | acute myeloid leukemia, myelodysplastic syndrome | Fox Chase Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02906800 | Jan 2017 → May 2019 | head and neck cancer | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT06701812 | Jan 2026 → Feb 2027 expected | medulloblastoma non-WNT/non-SHH | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06240403 | Sep 2025 → Aug 2028 expected | systolic heart failure, type 2 diabetes mellitus | University of Leeds | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06588699 | Jun 2025 → Jan 2029 expected | metabolic dysfunction-associated steatohepatitis | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT07047209 | May 2025 → Mar 2026 overdue | amyotrophic lateral sclerosis | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07307131 | Sep 2024 → Mar 2025 | common wart, human papilloma virus infection | Benha University | Completed | No outcome recorded |
| Phase 2 | NCT04834557 | Nov 2021 → May 2022 | rheumatoid arthritis | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05014087 | Oct 2021 → Jun 2025 | alcoholic fatty liver disease, alcoholic hepatitis, drug-induced liver injury | Yale University | Terminated | No outcome recorded |
| Phase 2 | NCT04141995 | Feb 2021 → May 2025 | pancreatic adenocarcinoma | University of Nebraska | Terminated | No outcome recorded |
| Phase 2 | NCT04216693 | Jun 2020 → Dec 2022 | metabolic dysfunction-associated steatohepatitis | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Withdrawn | No outcome recorded |
| Phase 2 | NCT03684772 | Oct 2018 → Sep 2019 | actinic keratosis | Maruho Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03334240 | Oct 2017 → Oct 2018 | anogenital human papillomavirus infection | Maruho Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02333643 | Jan → Aug 2015 | benign neoplasm of skin | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02212639 | Sep 2014 → Jan 2019 | classic Kaposi sarcoma, endemic Kaposi sarcoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT01887288 | Apr 2013 → Nov 2015 | breast cancer | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01763931 | Jan 2013 → Apr 2016 | breast cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT01162135 | Sep 2010 → Mar 2013 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT00281021 | Feb 2006 → Dec 2010 | non-small cell lung carcinoma | University of Louisville | Terminated | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05540600 | Sep 2022 → Jan 2023 | atrial fibrillation | University of Monastir | Unknown | No outcome recorded |
| Phase 3 | NCT05287191 | Jan 2022 → Oct 2025 | atrial fibrillation | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
| Phase 3 | NCT01951079 | Nov 2013 → Nov 2014 | cardiac rhythm disease, hypotensive disorder | Meir Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00390546 | Oct 2006 → Aug 2010 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00000556 | Mar 1995 → Sep 2002 | atrial fibrillation | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000476 | Jun 1990 → Jun 1998 | cardiac rhythm disease, congestive heart failure | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07321509 | Dec 2025 → Dec 2027 expected | heart failure | Hospital General de Agudos "Dr. Cosme Argerich" | Recruiting | No outcome recorded |
| Phase 4 | NCT05469204 | Nov 2022 → Jul 2025 | — | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT03136068 | Feb 2017 → May 2018 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02743260 | Apr 2016 → Dec 2017 | — | University of Cologne | Completed | No outcome recorded |
| Phase 4 | NCT02046044 | Jan → Oct 2014 | heart failure | Kocaeli University | Unknown | No outcome recorded |
| Phase 4 | NCT01775839 | Jan 2013 → Apr 2014 | hypersensitivity reaction disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01005602 | Dec 2006 → Dec 2009 | heart failure | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT05741372 | Sep 2023 → Dec 2024 | cirrhosis of liver | Boehringer Ingelheim | Completed | No outcome recorded |
| — | NCT05507775 | Dec 2022 → Jun 2023 | thyroid carcinoma, nonmedullary, with or without cell oxyphilia | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT04513509 | Oct 2020 → Jun 2022 | atrial fibrillation | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT04221919 | Jan 2020 → Jan 2021 | strictly posterior acute myocardial infarction | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| — | NCT02248753 | Oct 2014 → Nov 2018 | atrial fibrillation | Maastricht University Medical Center | Completed | No outcome recorded |
| — | NCT02277249 | Oct 2012 → Oct 2014 | — | University of California, Los Angeles | Completed | No outcome recorded |
| — | NCT00578617 | Sep 2006 → Feb 2009 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00006330 | — | heart disorder | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 39 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03261570 Comparator | Jul 2017 → Jun 2022 | postural orthostatic tachycardia syndrome | New York Medical College | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06899061 Comparator | Mar 2025 → Feb 2026 overdue | high grade malignant neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03559868 Comparator | Mar 2021 → May 2023 | inflammatory disease | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03197324 Comparator | Jul → Sep 2017 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT01357811 Comparator | Aug → Nov 2011 | — | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00904176 Comparator | Jun → Aug 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02797145 Comparator | May 2016 → May 2018 | heart failure | Hospital Ana Nery | Unknown | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT02544815 Comparator | May 2023 → Jul 2025 | heart failure | University of Monastir | Unknown | No outcome recorded |
| Phase 3 | NCT03718273 Comparator | Oct 2018 → Feb 2022 | atrial fibrillation | Adolfo Fontenla | Completed | No outcome recorded |
| Phase 3 | NCT04308031 Comparator | Aug 2018 → Dec 2020 | atrial fibrillation, heart failure | Chun-Yao Huang | Unknown | No outcome recorded |
| Phase 3 | NCT03016819 Comparator | Aug 2017 → Dec 2027 expected | alveolar soft part sarcoma, leiomyosarcoma, synovial sarcoma | Advenchen Laboratories, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT02624765 Comparator | Feb 2016 → Mar 2024 | atrial flutter, hydrops fetalis | Edgar Jaeggi | Completed | No outcome recorded |
| Phase 3 | NCT02132767 Comparator | May 2014 → Sep 2015 | atrial fibrillation | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT07238452 Comparator | Dec 2025 → Dec 2032 expected | atrial fibrillation, symptomatic heart failure | University of British Columbia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03783429 Comparator | Jul 2020 → Nov 2025 | heart failure | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 4 | NCT05391893 Comparator | Jun 2020 → Apr 2023 | atrial fibrillation, atrial flutter | Corewell Health South | Completed | No outcome recorded |
| Phase 4 | NCT04092621 Comparator | Sep 2019 → Sep 2020 | atrial fibrillation, infectious disease with sepsis, respiratory failure | Our Lady of the Lake Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02391337 Comparator | Dec 2016 → Apr 2019 | atrial fibrillation | University of Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT01774656 Background | Jan 2013 → Dec 2017 | advanced heart failure | University of Louisville | Unknown | No outcome recorded |
| Phase 4 | NCT02489786 Comparator | Oct 2012 → Oct 2014 | atrial fibrillation | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT01341353 Comparator | Apr 2011 → Dec 2014 | atrial fibrillation | Wuhan University | Unknown | No outcome recorded |
| Phase 4 | NCT01181414 Comparator | Oct 2010 → Nov 2014 | atrial fibrillation, dilated cardiomyopathy, heart failure | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT01699776 Comparator | Apr 2008 → Feb 2012 | heart failure | Cocco, Giuseppe, M.D. | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT07272902 Comparator | Jan 2026 → Oct 2027 expected | atrial fibrillation, diastolic heart failure, mild heart failure | Nova Scotia Health Authority | Recruiting | No outcome recorded |
| — | NCT06657404 Background | Oct → Dec 2024 overdue | atrial fibrillation | Yumei Xue | Recruiting | No outcome recorded |
| — | NCT06322017 Comparator | Apr 2024 → Apr 2030 expected | atrial fibrillation | Nantes University Hospital | Recruiting | No outcome recorded |
| — | NCT05599971 Comparator | Feb → Nov 2023 | plantar wart | Zagazig University | Unknown | No outcome recorded |
| — | NCT05520658 Comparator | Jul → Sep 2022 | plantar wart | Sohag University | Unknown | No outcome recorded |
| — | NCT04893629 Comparator | May 2021 → Nov 2024 | cardiomyopathy | Damascus University | Terminated | No outcome recorded |
| — | NCT04694092 Comparator | Nov 2020 → Dec 2023 | atrial fibrillation, left ventricular failure | Institute for Clinical and Experimental Medicine | Unknown | No outcome recorded |
| — | NCT02515526 Comparator | Jun → Aug 2015 | — | University of Cologne | Completed | No outcome recorded |
| — | NCT02220335 Background | Aug 2014 → Jun 2018 | pulmonary hypertension | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
| — | NCT01615731 Background | May 2012 → Jun 2013 | — | Stanford University | Completed | No outcome recorded |
| — | NCT01398371 Comparator | Aug 2011 → Feb 2015 | heart failure | The Alfred | Completed | No outcome recorded |
| — | NCT01047748 Comparator | Jan 2011 → Jan 2013 | — | White, Katharine O'Connell, M.D., M.P.H. | Completed | No outcome recorded |
| — | NCT00911508 Comparator | Nov 2009 → Dec 2017 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00940056 Background | Nov 2009 → May 2014 | atrial fibrillation | Region Örebro County | Completed | No outcome recorded |
| — | NCT00878384 Comparator | Apr 2009 → Jun 2012 | atrial fibrillation, heart failure | Royal Brompton & Harefield NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT01411371 Comparator | Mar 2005 → Oct 2011 | heart failure, persistent atrial fibrillation | Barts & The London NHS Trust | Unknown | No outcome recorded |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 243 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Digoxin | “The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ...” NCT01774656 ↗236“Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014 “A Phase 2, Randomized, Vehicle-controlled, Double-blind Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of...” NCT03334240 ↗ “Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as...” NCT01411371 ↗ “The BTZ-043 groups also received oral dolutegravir (a third of participants) or a probe drug cocktail (caffeine [probe for CYP1A2], tolbutamide [CYP2C9], dextromethorphan...” PMID 39793592 ↗ Jan 2025 “A single dose of selective substrates (probe drugs) was administered orally on days 15 and 30: caffeine (CYP1A2), tolbutamide (CYP2C9), omeprazole (CYP2C19), dextromethorphan...” PMID 37768317 ↗ Sep 2023 “In the main trial, patients with left ventricular ejection fractions of 0.45 or less were randomly assigned to digoxin (3397 patients) or placebo (3403 patients) in addition to...” NCT00000476 ↗ “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277 ↗ “Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.” NCT05395117 ↗ “Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg” NCT02045966 ↗ “This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.” NCT05391893 ↗ “Co-administered drugs include: - Warfarin - 10 mg tablets, midazolam 1 mg, digoxin 0.25 mg, rosuvastatin 10 mg, omeprazole 20 mg, Vitamin K - 10 mg.” NCT06975605 ↗ “Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed” NCT02132767 ↗ “Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.” NCT06533280 ↗ “one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin” NCT04092621 ↗ “Intensive heart rate control preferably with the use of short-acting betablocker landiolol in combination with digoxin” NCT04694092 ↗ “All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up.” NCT00940056 ↗ “Furosemide 20mg/2ml and digoxin 0.5mg/2ml given 0.2 ml into the wart base once weekly for 5 weeks” NCT06821594 ↗ “BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)” NCT03561298 ↗ “Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)” NCT05657613 ↗ “Period 1: One single dose of rosuvastatin and one single dose of digoxin on Day 1.” NCT05763459 ↗ “these agents may be combined with digoxin (trough target 0.5 and 0.9 ng/ml)” NCT07238452 ↗ “Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg” NCT04233437 ↗ “Decitabine will be administered in combination with Digoxin” NCT03113071 ↗ “Verapamil 180-240mg, Digoxin 0.125-0.25mg” NCT00911508 ↗ “Typical does: Digoxin 62.5-250mcg o.d.” NCT00878384 ↗ “Digoxin topical formulation” NCT02333643 ↗ “digoxin, and rosuvastatin” NCT03720366 ↗ “Digoxin Topical Gel” NCT03684772 ↗ “Digoxin 0.125mg” NCT00578617 ↗ “Drug: Digoxin” NCT07570082 ↗ “Digoxin” NCT02220335 ↗ |
| Known as | Digamex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Digaoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01341353 ↗ |
| Known as | Digoxin pediatric | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Digoxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | digoxine | “Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg” NCT01443039 ↗ |
| Known as | Digoxinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Dynamos | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Fargoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Lanocardin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Lanoxicaps | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Lanoxin | “Single-dose Digoxin (Lanoxin®), a Sensitive P-glycoprotein (P-gp) Substrate” NCT02300350 ↗3“Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose” NCT02456844 ↗ “LANOXIN® (digoxin) USP 250 mcg (Substrate drug)” NCT03909529 ↗ “digoxin (Lanoxin®) 0.125 mg QD” NCT00831506 ↗ |
| Known as | Lanoxin pediatric | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Lanoxin-125 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Lanoxin-pg | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Lenoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04590937 ↗ |
| Known as | Mapluxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Natigoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | nativelle | “Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg” NCT01443039 ↗ |
| Known as | NSC-95100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Rougoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Stillacor- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Toloxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | Vanoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1751 ↗ |
| Known as | β -Blockers | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04221919 ↗ |
| Action | Inhibit | “Digoxin is a sodium-potassium exchange pump inhibitor” NCT00390546 ↗ |
| Modality | Other / unclassified | “Preclinical data shows that CTC clusters can be disaggregated into single cells by the treatment with cardiac glycosides such as digoxin.” NCT03928210 ↗ |
| Route | Oral | “digoxin (0.5mg po)” NCT00504413 ↗ |
| Target | HIF1A | “The identification of HIF-1 alpha as a key factor in HHV8 replication prompt us to explore inhibition of HIF-1 alpha by digoxin as a potential therapeutic approach for KS...” NCT02212639 ↗ |